Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Evoke Pharma (EVOK)

Evoke Pharma (EVOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Evoke Pharma 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075 USA

www.evokepharma.com Employees: 3 P: 858-345-1494

Sector:

Medical

INDUSTRY GROUPING:

Medical - Generic Drugs

Description:

Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.

Key Statistics

Overview:

Market Capitalization, $K 18,946
Enterprise Value, $K 5,346
Shares Outstanding, K 1,722
Float, K 1,683
% Float 97.71%
Short Interest, K 11
Short Float 0.00%
Days to Cover 1.00
Short Volume Ratio 0.29
% of Insider Shareholders 2.29%
% of Institutional Shareholders 0.00%

Financials:

Annual Sales, $ 10,250 K
Annual Net Income, $ -5,350 K
Last Quarter Sales, $ 4,280 K
Last Quarter Net Income, $ -1,160 K
EBIT, $ -5,190 K
EBITDA, $ -5,190 K

Growth:

1-Year Return 139.73%
3-Year Return -65.01%
5-Year Return -97.28%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 93.91%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.45 on 11/13/25
Next Earnings Date 03/12/26
Earnings Per Share ttm -2.07
EPS Growth vs. Prev Qtr 27.42%
EPS Growth vs. Prev Year 52.13%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-12 on 08/01/24

EVOK Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -101.40%
Return-on-Assets % -31.86%
Profit Margin % -52.20%
Debt/Equity 0.00
Price/Sales 1.84
Price/Cash Flow N/A
Price/Book 5.10
Book Value/Share 2.15
Interest Coverage -9.70
60-Month Beta -0.15
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar